News

Updates from the 2020 American Society of Hematology Annual Meeting

Widely regarded as the premier event in malignant and non-malignant hematology, the ASH Meeting provided a critical forum for leading hematologists/ oncologists to present their findings to over 20,000 of their peers.

ASH 2020: Retrospective Study Reveals Transplant Potentially Curative for Mature T-cell Lymphoma

Allogeneic hematopoietic stem cell transplant (allo-HSCT) may be a successful curative treatment for T-cell patients with poor survival and/or limited treatment options, according to a retrospective study led by LRF grantee Neha Mehta-Shah, MD of the Washington University School of Medicine in St. Louis.

ASH 2020: Transplant Increases Overall Survival in Older, High-Risk Patients with Myelodysplastic Syndromes

Myelodysplastic Syndromes (MDS), also known as “bone marrow failure disorder,” are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells.

ASH 2020: BTK Inhibitor Shows Promise in Previously Treated Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma and other Non-Hodgkin Lymphomas

Researchers in BRUIN trial reveals promising data on BTK inhibitor in treatment for CLL, MCL and WM

ASH 2020: Early Trial for Bispecific Antibody in Non-Hodgkin Lymphoma Shows High Response Rate

Odronextamab, a bispecific antibody targeting CD20 and CD3, led to response rates as high as 90 percent in patients with refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients who underwent chimeric antigen receptor (CAR) T cell therapy, according to early trials results.

ASH 2020: Chemotherapy-Free Combination Treatment for Chronic Lymphocytic Leukemia Reveals High One-Year Disease-Free Survival Rate

A time-limited, frontline combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) shows to mobilize and clear CLL leading to deep responses for patients who achieved undetectable minimal residual disease (MRD) status, according to results from the CAPTIVATE study.

ASH 2020: ZUMA-12 Trial Exhibits Promising Results in Frontline CAR T Treatment for Aggressive Lymphoma

Axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, appeared an effective frontline (initial) treatment for high-risk large B-cell lymphomas.

Addressing Cancer Survivorship

Emily Tonorezos, MD, MPH, Director of the Office of Cancer Survivorship at the National Cancer Institute (NCI), in the Division of Cancer Control & Population Sciences, shares what she and the agency are doing to raise awareness of and address issues that cancer survivors may face, as well as future directions in cancer survivorship research.

Patient Perspectives: Understanding Telemedicine

With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.

U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (liso-cel, BREYANZI) for Large B-cell Lymphoma

Lisocabtagene maraleucel (BREYANZI) is the fourth chimeric antigen receptor (CAR) T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.